Announcements Trials
Browse Landscape

Phase

Phase 2 71Phase 1/2 24Phase 3 8Phase 1 7Phase 2/3 4Phase 4 2Phase NA 1Phase EARLY_PHASE1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Skin Neoplasms 2

Interventions

Saline Solution 10Docetaxel 10Bevacizumab 9nilotinib 8enzalutamide 8Paclitaxel 8Letrozole 8Fentanyl 8Everolimus 8Cyclophosphamide 8Carboplatin 8Bupivacaine 8Lidocaine 7Sodium Chloride 6Oxycodone 6Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 6Erlotinib Hydrochloride 6Dexamethasone 6Capecitabine 6Trastuzumab 5Tobacco Use Cessation Devices 5Surveys and Questionnaires 5Nivolumab 5Hydromorphone 5Adalimumab 5fludarabine 4Zoledronic Acid 4Tranexamic Acid 4Tacrolimus 4Rocuronium 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Has results × Sirolimus × Clear all
NCT00866684 2025-03-14

PROSKIN

Charite University, Berlin, Germany

Phase 4 Terminated
44 enrolled 7 charts
Dermatologic

Skin Neoplasms

NCT00129961 2012-04-11

Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 4 Completed
86 enrolled 22 charts
Dermatologic

Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡